Soleno Therapeutics
Market Cap
US$63.0m
Last Updated
2019/11/11 00:25 UTC
Data Sources
Company Financials +
Executive Summary
Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Snowflake
Fundamentals
Adequate balance sheet with moderate growth potential.
Share Price & News
How has Soleno Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SLNO's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-9.0%
SLNO
1.0%
US Biotechs
0.3%
US Market
1 Year Return
-34.7%
SLNO
6.7%
US Biotechs
12.5%
US Market
Return vs Industry: SLNO underperformed the US Biotechs industry which returned 6.7% over the past year.
Return vs Market: SLNO underperformed the US Market which returned 12.5% over the past year.
Shareholder returns
| SLNO | Industry | Market | |
|---|---|---|---|
| 7 Day | -9.0% | 1.0% | 0.3% |
| 30 Day | -12.7% | 11.0% | 4.1% |
| 90 Day | -27.7% | 5.2% | 5.6% |
| 1 Year | -34.7%-34.7% | 7.6%6.7% | 15.0%12.5% |
| 3 Year | -71.2%-71.2% | 12.4%8.9% | 49.1%39.4% |
| 5 Year | -93.0%-93.0% | 6.4%1.4% | 62.8%44.7% |
Price Volatility Vs. Market
How volatile is Soleno Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Will Soleno Therapeutics (NASDAQ:SLNO) Spend Its Cash Wisely?1 month ago | Simply Wall St
What Kind Of Investor Owns Most Of Soleno Therapeutics, Inc. (NASDAQ:SLNO)?3 months ago | Simply Wall St
How Many Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Did Insiders Buy, In The Last Year?Valuation
Is Soleno Therapeutics undervalued compared to its fair value and its price relative to the market?
3.24x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SLNO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SLNO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SLNO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: SLNO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SLNO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SLNO is overvalued based on its PB Ratio (3.2x) compared to the US Biotechs industry average (2.8x).
Next Steps
Future Growth
How is Soleno Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
72.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SLNO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).
Earnings vs Market: SLNO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SLNO's is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if SLNO's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if SLNO's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SLNO's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Soleno Therapeutics performed over the past 5 years?
-4.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SLNO has high quality earnings.
Growing Profit Margin: Insufficient data to determine if SLNO's profit margins have improved over the past year.
Past Earnings Growth Analysis
Earnings Trend: SLNO is unprofitable, and losses have increased over the past 5 years at a rate of -4.5% per year.
Accelerating Growth: Unable to compare SLNO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SLNO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (67.8%).
Return on Equity
High ROE: SLNO has a negative Return on Equity (-136.92%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Soleno Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: SLNO's short term assets ($16.6M) exceeds its short term liabilities ($2.9M)
Long Term Liabilities: SLNO's short term assets (16.6M) do not cover its long term liabilities (17.4M)
Debt to Equity History and Analysis
Debt Level: SLNO is debt free.
Reducing Debt: SLNO has no debt compared to 5 years ago when its debt to equity ratio was 17.2%.
Balance Sheet
Inventory Level: SLNO has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if SLNO's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SLNO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if SLNO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Soleno Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate SLNO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate SLNO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SLNO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SLNO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SLNO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Soleno Therapeutics's salary, the management and board of directors tenure and is there insider trading?
3.5yrs
Average management tenure
CEO
Anish Bhatnagar (49yo)
5.8yrs
Tenure
US$951,911
Compensation
Dr. Anish Bhatnagar, M.D. has been the Chief Executive Officer of Soleno Therapeutics, Inc. since February 6, 2014, President since December 31, 2013. Dr. Bhatnagar has been Director at Soleno Therapeutics ...
CEO Compensation Analysis
Compensation vs Market: Anish's total compensation ($USD951.91K) is above average for companies of similar size in the US market ($USD505.79K).
Compensation vs Earnings: Anish's compensation has been consistent with company performance over the past year.
Management Age and Tenure
3.5yrs
Average Tenure
58.5yo
Average Age
Experienced Management: SLNO's management team is considered experienced (3.5 years average tenure).
Board Age and Tenure
5.4yrs
Average Tenure
59yo
Average Age
Experienced Board: SLNO's board of directors are considered experienced (5.4 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Company |
| Shares | 8,764 |
| Max Price | US$1.55 |
| Entity | Company |
| Shares | 334,417 |
| Max Price | US$1.58 |
| Entity | Company |
| Shares | 2,300,000 |
| Max Price | US$1.20 |
| Entity | Company |
| Shares | 30,547 |
| Max Price | US$1.60 |
| Entity | Company |
| Shares | 57,069 |
| Max Price | US$2.14 |
| Entity | Company |
| Shares | 90,724 |
| Max Price | US$1.98 |
| Entity | Company |
| Shares | 130,363 |
| Max Price | US$1.22 |
| Entity | Company |
| Shares | 4,669,272 |
| Max Price | US$1.60 |
| Entity | Individual |
| Shares | 3,031,002 |
| Max Price | US$1.61 |
| Entity | Company |
| Shares | 1,245,135 |
| Max Price | US$1.61 |
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 75.9%.
Management Team
Jon Wolter (69yo)
CFO & Principal Accounting Officer
- Tenure: 2.2yrs
- Compensation: US$288.00k
Anish Bhatnagar (49yo)
President
- Tenure: 5.8yrs
- Compensation: US$951.91k
David O'Toole (60yo)
Consultant
- Tenure: 2.2yrs
- Compensation: US$358.00k
Neil Cowen
Senior Vice President of Drug Development
- Tenure: 0yrs
Tony Wondka (57yo)
Senior Vice President of Research & Development
- Tenure: 4.8yrs
- Compensation: US$270.00k
Patricia Hirano
Head of Regulatory Affairs and Quality
- Tenure: 0yrs
Board Members
Ernie Mario (80yo)
Independent Chairman
- Tenure: 5.8yrs
- Compensation: US$83.83k
Bill Harris (61yo)
Independent Director
- Tenure: 5.4yrs
- Compensation: US$75.94k
Stuart J. Collinson (59yo)
Independent Director
- Tenure: 2.7yrs
- Compensation: US$60.91k
Thomas Casale
Member of Advisory Board
- Tenure: 0yrs
Andrew Sinclair (47yo)
Independent Director
- Tenure: 0.9yrs
- Compensation: US$20.23k
Anish Bhatnagar (49yo)
President
- Tenure: 5.8yrs
- Compensation: US$951.91k
Robert Christensen
Member of Advisory Board
- Tenure: 0yrs
Vinny Bhutani
Member of Advisory Board
- Tenure: 0yrs
Glenis Scadding
Member of Advisory Board
- Tenure: 0yrs
David Stevenson
Member of Advisory Board
- Tenure: 0yrs
Company Information
Soleno Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Soleno Therapeutics, Inc.
- Ticker: SLNO
- Exchange: NasdaqCM
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$62.968m
- Shares outstanding: 44.66m
- Website: https://www.soleno.life
Number of Employees
Location
- Soleno Therapeutics, Inc.
- 1235 Radio Road
- Suite 110
- Redwood City
- California
- 94065
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SLNO | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Nov 2014 |
| 6XC1 | BST (Boerse-Stuttgart) | Yes | Common Stock | DE | EUR | Nov 2014 |
| 6XC1 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Nov 2014 |
Biography
Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, Diazoxide Choline Controlled Release (DCCR ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/11/11 00:25 |
| End of Day Share Price | 2019/11/08 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.